REG - Silence Therapeutics - Holding(s) in Company

Silence TherapeuticsAnnouncement

06/08/2021 12:20

RNS Number : 8832H
  
Silence Therapeutics PLC
  
06 August 2021
  
 

TR-1: Standard form for notification of major holdings 

1. Issuer Details 



ISIN 


GB00B9GTXM62 


Issuer Name 


SILENCE THERAPEUTICS PLC 


UK or Non-UK Issuer 


UK 



2. Reason for Notification 


An acquisition or disposal of voting rights 


3. Details of person subject to the notification obligation 



Name 


Societe Generale 


City of registered office (if applicable) 


London 


Country of registered office (if applicable) 


United Kingdom 



4. Details of the shareholder 



Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above 


 


City of registered office (if applicable) 


 


Country of registered office (if applicable) 


 



5. Date on which the threshold was crossed or reached 


30-Jul-2021 


6. Date on which Issuer notified 


02-Aug-2021 


7. Total positions of person(s) subject to the notification obligation 







% of voting rights attached to shares (total of 8.A) 


% of voting rights through financial instruments (total of 8.B 1 + 8.B 2) 


Total of both in % (8.A + 8.B) 


Total number of voting rights held in issuer 




Resulting situation on the date on which threshold was crossed or reached 


5.100000 


0.000000 


5.100000 


4575602 




Position of previous notification (if applicable) 




















8. Notified details of the resulting situation on the date on which the threshold was crossed or reached 


8A. Voting rights attached to shares 





Class/Type of shares ISIN code(if possible) 


Number of direct voting rights (DTR5.1) 


Number of indirect voting rights (DTR5.2.1) 


% of direct voting rights (DTR5.1) 


% of indirect voting rights (DTR5.2.1) 




GB00B9GTXM62 


4575602 


0 


5.100000 


0.000000 




Sub Total 8.A 


4575602 


5.100000% 





8B1. Financial Instruments according to (DTR5.3.1R.(1) (a)) 





Type of financial instrument 


Expiration date 


Exercise/conversion period 


Number of voting rights that may be acquired if the instrument is exercised/converted 


% of voting rights 


























Sub Total 8.B1 

















8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b)) 





Type of financial instrument 


Expiration date 


Exercise/conversion period 


Physical or cash settlement 


Number of voting rights 


% of voting rights 






























Sub Total 8.B2 

















9. Information in relation to the person subject to the notification obligation 


1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. 





Ultimate controlling person 


Name of controlled undertaking 


% of voting rights if it equals or is higher than the notifiable threshold 


% of voting rights through financial instruments if it equals or is higher than the notifiable threshold 


Total of both if it equals or is higher than the notifiable threshold 



























10. In case of proxy voting 



Name of the proxy holder 


 


The number and % of voting rights held 


 


The date until which the voting rights will be held 


 



11. Additional Information 


 


12. Date of Completion 


03-Aug-2021 


13. Place Of Completion 


London, United Kingdom 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
HOLUNAARAUUWRAR